SCHEMBL23950267

SCHEMBL23950267

CC(CO)n1cnc2c(-c3cnn(C)c3)nc(-c3ccc(C(F)(F)F)cc3)cc2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 5/20 0.39
JAK2 O60674 3/20 0.39
JAK1 P23458 3/20 0.39
JAK3 P52333 3/20 0.39
PIK3CA P42336 2/20 0.39
MTOR P42345 2/20 0.39
EPHB4 P54760 1/20 0.38
TEK Q02763 1/20 0.38
FLT3 P36888 1/20 0.35
SYK P43405 1/20 0.35
AURKB Q96GD4 1/20 0.35
NPBWR1 P48145 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
MAPK1 P28482 2/20 0.34
TRPV3 Q8NET8 1/20 0.34
HSP90AA1 P07900 2/20 0.34
NTRK1 P04629 2/20 0.34
CSF1R P07333 2/20 0.34
NTRK2 Q16620 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23950500 0.97 PIK3CA (0.40) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23390352 0.92 PIK3CA (0.39) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL29610912 0.92 PIK3CA (0.39) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23390356 0.92 PIK3CA (0.39) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23390452 0.91 NTRK1 (0.39) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23390455 0.91 NTRK1 (0.39) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23950259 0.90 KDM5B (0.38) TRPV3PDE2A
SCHEMBL23925513 0.90 TYK2 (0.40) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23390156 0.89 ABL1 (0.40) TYK2JAK2JAK1JAK3PIK3CA
SCHEMBL23925567 0.89 JAK2 (0.45) TYK2JAK2JAK1JAK3PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 TYK2 1076/4885JAK2 919/4885JAK1 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.